Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.
Landen CN Jr, et al. Among authors: kinch ms.
J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70. doi: 10.1093/jnci/djj414.
J Natl Cancer Inst. 2006.
PMID: 17077358